Advertisement

Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population

  • Kei YoshimatsuEmail author
  • Andrea Elser
  • Melanie Thomas
  • James Dilley
  • Deborah Barnes
  • Alexandra Ballinger
  • Steven Wozniak
  • Christina Mangurian
Brief Report

Abstract

This study examined whether transitioning patients from oral antipsychotics (POs) to long-acting injectable antipsychotics (LAIs) helps patients achieve recovery-oriented goals. Data was extracted from San Francisco County’s electronic medical record system for this retrospective pre-post observational study. Patients reflect a safety-net population treated in community-based mental health settings during 2015. The San Francisco Adult Strengths and Needs Assessment (SF ANSA), a measure of psychosocial functioning, was used to assess within-subject change when treated with POs versus LAIs. In our study sample (N = 77), LAI SF ANSA scores showed significant improvements in criminal behaviors (p = .017), medication adherence (p = .008), and spirituality (p = .028), and a non-significant trend for residential stability (p = .073). This is the first study to evaluate improvements in key psychosocial areas after treatment with LAIs. This work suggests that LAIs can be another tool for providers to help patients work towards their recovery-oriented goals.

Keywords

Long-acting injectable antipsychotic medications Recovery Psychosis Schizophrenia Depot medications 

Notes

Compliance with Ethical Standards

Conflict of interest

Dr. Mangurian received salary support from NIH Grants (K23MH093689, R01MH112420, and R03DK101857). Dr. Barnes was supported by the UCSF Mental Health Biostatistics Core. Dr. Wozniak is an employee of Behavioral Health Services at the San Francisco Department of Public Health. Drs. Thomas and Dilley are employees of UCSF, Department of Psychiatry. Dr. Yoshimatsu, Ms. Elser, and Ms. Ballinger were supported by the UCSF-San Francisco General Hospital Public Psychiatry Fellowship. All authors report no financial relationships with commercial interests.

References

  1. Cohen, A. N., Hamilton, A. B., Saks, E. R., Glover, D. L., Glynn, S. M., Brekke, J. S., et al. (2016). How occupationally high-achieving individuals with a diagnosis of schizophrenia manage their symptoms. Psychiatric Services, 68(4), 324–329.  https://doi.org/10.1176/appi.ps.201600031.CrossRefGoogle Scholar
  2. Community Behavioral Health Services. (2010). ANSA Ratings: Adult/Older Adult Assessment. City and County of San Francisco Department of Public Health. Retrieved from https://www.sfdph.org/dph/comupg/oservices/mentalHlth/CBHS/default.asp.
  3. Gulcur, L., Stefancic, A., Shinn, M., Tsemberis, S., & Fischer Sean, N. (2003). Housing, hospitalization, and cost outcomes for homeless individuals with psychiatric disabilities participating in continuum of care and housing first programmes. Journal of Community & Applied Social Psychology, 13(2), 171–186.  https://doi.org/10.1002/casp.723.CrossRefGoogle Scholar
  4. Kane, J. M., Kishimoto, T., & Correll, C. U. (2013). Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of Clinical Epidemiology, 66, 37–41.CrossRefGoogle Scholar
  5. Kaplan, G., Casoy, J., & Zummo, J. (2013). Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence, 7, 1171–1180.  https://doi.org/10.2147/PPA.S53795.CrossRefGoogle Scholar
  6. Lindenmayer, J. P., Liu-Seifert, H., Kulkarni, P. M., Kinon, B. J., Stauffer, V., Edwards, S. E., et al. (2009). Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. Journal of Clinical Psychiatry, 70(7), 990–996.  https://doi.org/10.4088/JCP.08m04221.CrossRefGoogle Scholar
  7. Lynn Starr, H., Bermak, J., Mao, L., Rodriguez, S., & Alphs, L. (2017). Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study. Schizophrenia Research.  https://doi.org/10.1016/j.schres.2017.05.005.Google Scholar
  8. Lyons, J. S., & Anderson, R. L. (1999). San Francisco Adult Needs and Strengths Assessment SF ANSA Manual: An Information Integration Tool for Adults with Behavioral Health Challenges. Retrieved from https://praedfoundation.org/tools/the-adult-needs-and-strengths-assessment-SFANSA/SFANSA-california/.
  9. Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy, 21(9), 754–769.  https://doi.org/10.18553/jmcp.2015.21.9.754.CrossRefGoogle Scholar
  10. Miyamoto, S., & Wolfgang Fleischhacker, W. (2017). The use of long-acting injectable antipsychotics in schizophrenia. Current Treatment Options in Psychiatry, 4(2), 117–126.  https://doi.org/10.1007/s40501-017-0115-z.CrossRefGoogle Scholar
  11. Olson, B., & Allen, R. S. (2015). Validity of the adult needs and strengths assessment with substance abuse populations. Journal of Addiction Research & Therapy, 06(03), 235.  https://doi.org/10.4172/2155-6105.1000235.Google Scholar
  12. Rezansoff, S. N., Moniruzzaman, A., Fazel, S., Procyshyn, R., & Somers, J. M. (2016). Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: A 15-year retrospective cohort study. Social Psychiatry and Psychiatric Epidemiology, 51(12), 1623–1632.  https://doi.org/10.1007/s00127-016-1259-7.CrossRefGoogle Scholar
  13. Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L., Valley, D., et al. (2011). Long-acting risperidone and oral antipsychotics in unstable Schizophrenia. New England Journal of Medicine, 364(9), 842–851.  https://doi.org/10.1056/NEJMoa1005987.CrossRefGoogle Scholar
  14. Sajatovic, M., Ramirez, L. F., Fuentes-Casiano, E., Cage, J., Tatsuoka, C., Aebi, M. E., et al. (2017). A 6-month prospective trial of a personalized behavioral intervention + long-acting injectable antipsychotic in individuals with schizophrenia at risk of treatment nonadherence and homelessness. Journal of Clinical Psychopharmacology, 37(6), 702–707.  https://doi.org/10.1097/JCP.0000000000000778.CrossRefGoogle Scholar
  15. Thomas, E. C., Despeaux, K. E., Drapalski, A. L., & Bennett, M. (2017). Person-oriented recovery of individuals with serious mental illnesses: A review and meta-analysis of longitudinal findings. Psychiatric Services, 1, 1.  https://doi.org/10.1176/appi.ps.201700058.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kei Yoshimatsu
    • 1
    Email author
  • Andrea Elser
    • 1
  • Melanie Thomas
    • 1
  • James Dilley
    • 1
  • Deborah Barnes
    • 1
  • Alexandra Ballinger
    • 1
  • Steven Wozniak
    • 2
  • Christina Mangurian
    • 1
  1. 1.Department of PsychiatryUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Behavioral Health Services, San Francisco Department of Public HealthSan FranciscoUSA

Personalised recommendations